bibliographic resource 8212786 [br/8212786]
https://w3id.org/oc/corpus/br/8212786

is a
title
  • Faculty of 1000 evaluation for Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study.
publication date
  • 2013-01-01
contributor
identifier
part of